NCATS, in collaboration with other NIH Institutes and Centers, the Defense Advanced Research Projects Agency and the Food and Drug Administration, is leading the Tissue Chip for Drug Screening program to develop human tissue chips that accurately model the structure and function of human organs — such as the lung, liver and heart — to help predict drug safety in humans more rapidly and effectively. Currently, this program is focused on toxicity testing. Plans are underway to renew the program with a focus on disease modeling and efficacy testing.
- Tissue Chip Development
- Tissue Chip Testing Centers
- Tissue Chips in Space
- Tissue Chips for Disease Modeling and Efficacy Testing
The first two-year funding phase of the Tissue Chip for Drug Screening program (2012-2014) supported the development of 3-D cellular microsystems designed to represent a number of human organ systems. Renewable cell sources and bioengineered microsystems that successfully demonstrated physiological function moved into the next three-year phase (2015-2017) to further refine the technology and begin organ chip integration, with the first five years of the program drawing to a close in July 2017. Projects that explored the use of stem and progenitor cells to differentiate into multiple cell types that represent the cellular architecture within the organ were also awarded through this initiative. Learn more about Tissue Chip Development.
- View the 2014 projects to integrate tissue chips.
- View the 2012 projects on model systems.
- View the 2012 projects on cell resources.
Tissue Chip Testing Centers are based at independent institutions and provide a way to test and validate tissue chip platforms developed through the program. These efforts will help to validate tissue chip technology and promote the adoption of this technology by the broader research community. Learn more about Tissue Chip Testing Centers.
NCATS is partnering with the Center for the Advancement of Science in Space (CASIS) on its Tissue Chips in Space initiative. Through this initiative, NCATS and CASIS will collaborate to refine tissue- and organ-on-chip platforms for on-flight experiments at the International Space Station U.S. National Laboratory so that scientists can better understand diseases and translate those findings to improve human health on Earth. Learn more about Tissue Chips in Space.
The Tissue Chips for Disease Modeling initiative will support further development of tissue chip models of human disease that mimic the pathology in major human organs and tissues. The goals are to (1) support studies to develop in vitro disease models using primary tissue or induced pluripotent stem cell (iPSC)-derived patient cell sources on tissue/organ-on-chip platforms, (2) determine disease relevance of these models by preliminary testing of key experimental features and (3) test the effectiveness of candidate drugs. Learn more about Tissue Chips for Disease Modeling and Efficacy Testing.